A validation team is running performance qualification on a new isolator. The H₂O₂ cycle parameters are set, the biological indicators are in place, and the first runs are complete. Seven days later, the BI results come back – and several are positive.
The positives show no pattern. They are not clustered in one area. They appear at different locations across successive runs. The cycle parameters haven’t changed. The team begins investigating: is there a distribution issue? A dead spot? A problem with the injection system?
This is one of the most frustrating scenarios in cycle development – and it is more common than most teams expect.
The investigation
The team re-ran the qualification cycles with two changes:
- Enzyme Indicators were placed alongside BIs at every position. EIs provide a quantitative readout of H₂O₂ exposure in approximately 60 seconds – no incubation, no seven day wait.
- A second BI supplier was introduced to test whether the original lot was contributing to the inconsistency.
The EI results were clear: consistent, strong inactivation across all positions, including the locations where unexpected positives had previously appeared. The quantitative data showed no distribution weakness – every monitored point received robust exposure.
The second BI supplier produced no unexpected positives across the same set of runs.
What EI data changed
Without EIs, this team would have continued investigating a cycle fault that did not exist. The likely path: additional mapping runs, parameter adjustments, extended timelines – all chasing a problem in the process when the problem was in the indicator.
The EI data provided something BIs could not: an independent, quantitative confirmation that the cycle was delivering adequate exposure at every position. That evidence, combined with the second-supplier comparison, allowed the team to close the investigation with confidence and move forward.
Three practical takeaways from this project:
- EI data can resolve ambiguity that BIs alone cannot. When BI results are inconsistent, a quantitative exposure measurement gives you a second line of evidence to work with.
- Investigating BI failures without exposure data is slow and often circular. You end up adjusting cycle parameters based on incomplete information.
- Running EIs alongside BIs from the start builds the dataset that prevents these delays. If this team had collected EI data from the first qualification run, the investigation would have been shorter – the baseline exposure data would already have been in hand.
The broader point is not that BIs are unreliable. They remain the regulatory standard for microbial lethality confirmation. But when they produce unexpected results, having a complementary data source – one that is fast, quantitative, and position-specific transforms a weeks long investigation into a clear, evidence-based conclusion.
Next in the series: How EI data and CFD simulation arrived at the same answer – and what that convergence means for defensible validation.
